- RNA editing was framed as a potential “lock-in” technology that could create perpetual revenue streams for pharmaceutical companies, highlighting concerns about therapeutic dependency.  
- The open-source “Wuerstchen” image-generation model was cited as a cost benchmark: ~24 000 A100-hours (~US $40 k on vast.ai), producing SD-1.4-level quality after heavy aesthetic filtering, illustrating current training economics.  
- A GLP-1 analogue produced in E. coli (PMC5531477) was shared as an example of low-cost, long-acting diabetes therapy attainable with basic bio-foundry tools.  
- Akkermansia muciniphila (commercial source: Pendulum Glucose Control) was discussed as a microbiome route to raise endogenous GLP-1, with a claimed 0.6 % HbA1c reduction in trials; titration protocols remain unclear.  
- 3-D-printed Cas9 protein models were shown as educational artifacts, prompting a technical digression on defining primary, secondary, tertiary, and super-secondary structural features for physical representation.  
- Marshall Brain’s early-2000s essays on wholesale automation and societal transition were revisited as prescient guides for post-scarcity planning.  
- A debate on “humans as investment vehicles” used economic language to critique modern dating dynamics, birth-control effects on mate-selection strategies, and the limits of market metaphors in personal relationships.  
- The explosion of granular product variants (e.g., dozens of milk categories) was used to argue that monetary prices are losing cognitive tractability for individual decision-making, though others countered that only a tiny subset is ever relevant.